EP2066635A2 - 2-phenoxynikotinsäure-derivate und ihre verwendung - Google Patents

2-phenoxynikotinsäure-derivate und ihre verwendung

Info

Publication number
EP2066635A2
EP2066635A2 EP07801996A EP07801996A EP2066635A2 EP 2066635 A2 EP2066635 A2 EP 2066635A2 EP 07801996 A EP07801996 A EP 07801996A EP 07801996 A EP07801996 A EP 07801996A EP 2066635 A2 EP2066635 A2 EP 2066635A2
Authority
EP
European Patent Office
Prior art keywords
hydrogen
alkyl
fluorine
alkoxy
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07801996A
Other languages
German (de)
English (en)
French (fr)
Inventor
Heinrich Meier
Peter Kolkhof
Axel Kretschmer
Arounarith Tuch
Lars BÄRFACKER
Yolanda Cancho Grande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of EP2066635A2 publication Critical patent/EP2066635A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP07801996A 2006-09-12 2007-08-30 2-phenoxynikotinsäure-derivate und ihre verwendung Withdrawn EP2066635A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006043520A DE102006043520A1 (de) 2006-09-12 2006-09-12 2-Phenoxynikotinsäure-Derivate und ihre Verwendung
PCT/EP2007/007575 WO2008031501A2 (de) 2006-09-12 2007-08-30 2-phenoxynikotinsäure-derivate und ihre verwendung

Publications (1)

Publication Number Publication Date
EP2066635A2 true EP2066635A2 (de) 2009-06-10

Family

ID=38681456

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07801996A Withdrawn EP2066635A2 (de) 2006-09-12 2007-08-30 2-phenoxynikotinsäure-derivate und ihre verwendung

Country Status (11)

Country Link
US (1) US20100298221A1 (es)
EP (1) EP2066635A2 (es)
JP (1) JP2010507569A (es)
AR (1) AR062586A1 (es)
CA (1) CA2662879A1 (es)
CL (1) CL2007002637A1 (es)
DE (1) DE102006043520A1 (es)
PE (1) PE20081371A1 (es)
TW (1) TW200829553A (es)
UY (1) UY30582A1 (es)
WO (1) WO2008031501A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007042754A1 (de) 2007-09-07 2009-03-12 Bayer Healthcare Ag Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CN107375932B (zh) 2011-10-28 2021-12-21 夏尔人类遗传性治疗公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
EA029581B1 (ru) 2011-10-28 2018-04-30 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Применение ингибиторов рециркуляции желчных кислот для лечения холестатического заболевания печени или прурита
EP2968262A1 (en) 2013-03-15 2016-01-20 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
MX2021009622A (es) 2019-02-12 2021-11-04 Mirum Pharmaceuticals Inc Metodos para tratar la colestasis.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005531520A (ja) * 2002-03-28 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド 置換２，３−ジフェニルピリジン類
DE102005027150A1 (de) * 2005-03-12 2006-09-28 Bayer Healthcare Ag Pyrimidincarbonsäure-Derivate und ihre Verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008031501A2 *

Also Published As

Publication number Publication date
AR062586A1 (es) 2008-11-19
DE102006043520A1 (de) 2008-03-27
TW200829553A (en) 2008-07-16
CL2007002637A1 (es) 2008-03-14
JP2010507569A (ja) 2010-03-11
WO2008031501A2 (de) 2008-03-20
US20100298221A1 (en) 2010-11-25
WO2008031501A3 (de) 2011-04-14
CA2662879A1 (en) 2008-03-20
UY30582A1 (es) 2008-05-02
PE20081371A1 (es) 2008-10-16

Similar Documents

Publication Publication Date Title
DE102007042754A1 (de) Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
CN101466676B (zh) 吡啶基酰胺类t-型钙通道拮抗剂
WO2006097220A1 (de) Pyrimidincarbonsäure-derivate und ihre verwendung
WO2008031500A1 (de) 4-phenoxy-nikotinsäure-derivate und ihre verwendung als ppar-modulatoren
DE102007061757A1 (de) Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung
EP1797045A1 (de) Neue pyrimidin-derivate und ihre verwendung als ppar-alpha-modulatoren
EP2066635A2 (de) 2-phenoxynikotinsäure-derivate und ihre verwendung
DE102007009494A1 (de) Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
DE102007061756A1 (de) Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung
EP2297104A1 (de) 2-alkoxy-substituierte dicyanopyridine und ihre verwendung
DE102006026583A1 (de) Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
EP3337800B1 (de) Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamid und dessen aufreinigung für die verwendung als pharmazeutischer wirkstoff
WO2009080197A1 (de) Substituierte pyrrolo[2, 3-b]- und pyrazolo[3, 4-b] pyridine als adenosin rezeptor liganden
EP2086969B1 (de) 3-cyano-5-thiazaheteroaryl-dihydropyridine und ihre verwendung zur behandlung kardiovaskulärer erkrankungen
DE102005061170A1 (de) Neue, acyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung
EP2556856B1 (de) 6-Cyano-substituierte Pyrido[2,3-d]pyrimidine als Adenosin Rezeptor Liganden zur Behandlung von Kardiovaskulären Erkrankungen
DE102005061171A1 (de) Neue, cyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung
WO2006040002A1 (de) Neue oxadiazinon-derivate und ihre verwendung als ppar-alpha-modulatoren

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
R17D Deferred search report published (corrected)

Effective date: 20110414

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT

18D Application deemed to be withdrawn

Effective date: 20110301